Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
397
-
Total 13F shares, excl. options
-
113M
-
Shares change
-
-174K
-
Total reported value, excl. options
-
$16.5B
-
Value change
-
-$76.9M
-
Put/Call ratio
-
0.62
-
Number of buys
-
175
-
Number of sells
-
-211
-
Price
-
$145.85
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2022
512 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2022.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 397 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113M shares
of 132M outstanding shares and own 85.89% of the company stock.
Largest 10 shareholders include FMR LLC (14.3M shares), VANGUARD GROUP INC (11M shares), Capital World Investors (10.3M shares), BAILLIE GIFFORD & CO (9.97M shares), BlackRock Inc. (7.66M shares), PRICE T ROWE ASSOCIATES INC /MD/ (7M shares), WELLINGTON MANAGEMENT GROUP LLP (5.81M shares), Dodge & Cox (5.26M shares), STATE STREET CORP (2.99M shares), and JPMORGAN CHASE & CO (2.28M shares).
This table shows the top 397 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.